Needham Rates Carlsmed (CARL) buy, $17 Price Target

Analyst David Saxon of Needham maintains a buy rating on CARL with a $17 target, a 63.78% upside from the current price.

By TradeTexts Research Desk · Published Jul 1, 2026, 8:00 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Needham rated Carlsmed, Inc. ($CARL) "buy" with a $17 price target on July 1, 2026.

Since the rating, $CARL is up 3.4% after 1 week, up 7.5% after 1 month and up 14.5% to date (from the $11.71 close on Jul 1, 2026).

CARL Carlsmed, Inc.

$13.41 +15.31% year to date

Daily close · Oct 16, 2026

Key Points

Needham's David Saxon reiterated a buy rating on CARL with a $17 price target on July 1, 2026.
Needham's $17 price target implies 63.78% upside from Carlsmed, Inc.'s ($CARL) current $10.38 share price.
Shares of CARL traded near $10.38 on Wednesday, reflecting ongoing interest from investors.
Institutional activity shows Janus Henderson grew its CARL holdings by 86,834 shares, now worth about $11.1 million.

Get $CARL trade alerts by text

We text you when insiders, Congress or big funds trade $CARL. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Carlsmed, Inc. alert may contain errors. Disclosures

On July 1, 2026, Needham analyst David Saxon reiterated his buy rating on CARL, setting a price target of $17. This decision underscores continued confidence in the stock's potential growth.

Analyst rating track record

Needham vs. the S&P 500

YTD return +19.78% hypothetical

All-time return +90.87% S&P 500 +28.66%

vs. S&P 500 +62.21% ahead of the index

Hypothetical returns from Needham's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in CARL

Institutional investors have shown varied interest in CARL recently. Orbimed Advisors LLC held steady with 1,252,600 shares valued at approximately $11.3 million. Janus Henderson Group PLC increased its position by 86,834 shares, bringing its total to 1,227,452 shares worth about $11.1 million. Parkman Healthcare Partners LLC opened a new position with 521,123 shares valued at $4.7 million. BlackRock, Inc. added 19,418 shares, ending with 446,892 shares valued at roughly $4 million. Schonfeld Strategic Advisors LLC also initiated a new stake with 283,180 shares, valued at $2.6 million.

Carlsmed, Inc. Stock Down 33.4%

Shares of CARL traded near $10.38 on Wednesday. Despite lacking details on market cap and P/E ratios, the stock's activity reflects investor interest. The presence of notable institutional investors suggests confidence in its future performance.

12-month forecast

$CARL price target

Carlsmed, Inc. daily closes and this analyst's $17 target. Not advice.

Analysts Set New Price Targets

On July 1, 2026, Needham's David Saxon reiterated a buy rating on CARL with a $17 price target. BTIG also reiterated a buy rating on May 6, 2026, with a target of $23. Truist Securities maintained its buy rating on April 15, 2026, setting a target of $18, while Goldman Sachs maintained a buy rating with a $17 target on April 9, 2026. The consensus among analysts remains positive, with a general buy recommendation.

Bottom Line

Needham's reiteration of a buy rating for CARL, along with a $17 price target, highlights ongoing optimism from analysts. Institutional investors' varied activity further suggests a mixed but generally positive outlook. As always, 13F filings and analyst ratings provide historical perspectives and are not indicative of future performance.